{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:48:47Z","timestamp":1788025727783,"version":"build-2784847793"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["211182\/Z\/18\/Z"],"award-info":[{"award-number":["211182\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Center","doi-asserted-by":"publisher","award":["Senior Fellowship"],"award-info":[{"award-number":["Senior Fellowship"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aims:<\/jats:bold> Deprescribing of antihypertensive drugs is recommended for some older patients with polypharmacy, but there is little evidence to inform which drug (or dose) should be withdrawn. This study used data from the OPTiMISE trial to examine whether short-term outcomes of deprescribing vary by drug class and dose of medication withdrawn.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The OPTiMISE trial included patients aged \u226580\u00a0years with controlled systolic blood pressure (SBP; &amp;lt;150\u00a0mmHg), receiving \u22652 antihypertensive medications. This study compared SBP control, mean change in SBP and frequency of adverse events after 12\u00a0weeks in participants stopping one medication vs. usual care, by drug class and equivalent dose of medication withdrawn. Equivalent dose was determined according to the defined daily dose (DDD) of each medication type. Drugs prescribed below the DDD were classed as low dose and those prescribed at \u2265DDD were described as higher dose. Outcomes were examined by generalized linear mixed effects models.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 569 participants were randomized, aged 85 \u00b1 3\u00a0years with controlled blood pressure (mean 130\/69\u00a0mmHg). Within patients prescribed calcium channel blockers, higher dose medications were more commonly selected for withdrawal (90 vs. 10%). In those prescribed beta-blockers, low dose medications were more commonly chosen (87 vs. 13%). Withdrawal of calcium channel blockers was associated with an increase in SBP (5\u00a0mmHg, 95%CI 0\u201310\u00a0mmHg) and reduced SBP control (adjusted RR 0.89, 95%CI 0.80\u20130.998) compared to usual care. In contrast, withdrawal of beta-blockers was associated with no change in SBP (\u22124\u00a0mmHg, 95%CI \u221210 to 2\u00a0mmHg) and no difference in SBP control (adjusted RR 1.15, 95%CI 0.96\u20131.37). Similarly, withdrawal of higher dose medications was associated with an increase in SBP but no change in BP control. Withdrawal of lower dose medications was not associated with a difference in SBP or SBP control. There was no association between withdrawal of specific drug classes and adverse events.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> These exploratory data suggest withdrawal of higher dose calcium channel blockers should be avoided if the goal is to maintain BP control. However, low dose beta-blockers may be removed with little impact on blood pressure over 12-weeks of follow-up. Larger studies are needed to confirm these associations.<\/jats:p>","DOI":"10.3389\/fphar.2021.619088","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T08:17:04Z","timestamp":1618906624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"James P.","family":"Sheppard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. D. Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert A.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the OPTiMISE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"The Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/nejmoa0801369","article-title":"Treatment of hypertension in patients 80\u00a0years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1097\/hjh.0b013e328339f9c5","article-title":"Treatment of hypertension in patients 80\u00a0years and older: the lower the better? A meta-analysis of randomized controlled trials","volume":"28","author":"Bejan-Angoulvant","year":"2010","journal-title":"J. Hypertens."},{"key":"B4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1161\/HYPERTENSIONAHA.115.07020","article-title":"An expert opinion from the European society of hypertension-European union geriatric medicine society working group on the management of hypertension in very old, frail subjects","volume":"67","author":"Benetos","year":"2016","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","article-title":"Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents","volume":"175","author":"Benetos","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5414\/cpp46072","article-title":"STOPP (screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation","volume":"46","author":"Gallagher","year":"2008","journal-title":"Cp"},{"key":"B8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.11909\/j.issn.1671-5411.2018.04.011","article-title":"Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure","volume":"15","author":"Gulla","year":"2018","journal-title":"J. Geriatr. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41440-020-0510-5","article-title":"Frailty and hypertension in older adults: current understanding and future perspectives","volume":"43","author":"Liu","year":"2020","journal-title":"Hypertens. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12916-017-0988-0","article-title":"Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial","volume":"16","author":"Luymes","year":"2018","journal-title":"BMC Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e012690","DOI":"10.1136\/bmjopen-2016-012690","article-title":"Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study","volume":"6","author":"Mansfield","year":"2016","journal-title":"BMJ open"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00126097-200402000-00009","article-title":"Overall accuracy of the BpTRU\u2013an automated electronic blood pressure device","volume":"9","author":"Mattu","year":"2004","journal-title":"Blood Press. Monit."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/bmj.333.7557.8-a","article-title":"NICE removes beta blockers as first line treatment for hypertension","volume":"333","author":"Mayor","year":"2006","journal-title":"BMJ (Clinical research ed)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1001\/jamainternmed.2015.4103","article-title":"Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning-the DANTE study leiden","volume":"175","author":"Moonen","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"B18","first-page":"e000406","volume-title":"Multimorbidity: assessment, prioritisation and management of care for people with commonly occurring multimorbidity [NICE guideline 56]","year":"2016"},{"key":"B19","volume-title":"National Institute for health and care excellence. Hypertension in adults: diagnosis and management [NICE guideline 136]","year":"2019"},{"key":"B20","volume-title":"Guideline for the diagnosis and management of hypertension in adults, Melbourne","year":"2016"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"B22","volume-title":"British national formulary","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/DHPS.S45347","article-title":"Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study","volume":"5","author":"Sato","year":"2013","journal-title":"Drug Healthc. Patient Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e022930","DOI":"10.1136\/bmjopen-2018-022930","article-title":"OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial","volume":"8","author":"Sheppard","year":"2018","journal-title":"BMJ open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1111\/jgs.16749","article-title":"Generalizability of blood pressure lowering trials to older patients: cross\u2010sectional analysis","volume":"68","author":"Sheppard","year":"","journal-title":"J. Am. Geriatr. Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1001\/jama.2020.16441","article-title":"Deprescribing antihypertensive medication in elderly adults-reply","volume":"324","author":"Sheppard","year":"","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1001\/jama.2020.4871","article-title":"Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 Years and older","volume":"323","author":"Sheppard","year":"","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e4535","DOI":"10.1136\/bmj.e4535","article-title":"Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study","volume":"345","author":"Sheppard","year":"2012","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/agm2.12045","article-title":"Factors associated with medication adherence in older patients: a systematic review","volume":"1","author":"Smaje","year":"2018","journal-title":"Aging Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Sprint Investigators","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/01.str.30.8.1538","article-title":"Use of the Barthel index and modified Rankin scale in acute stroke trials","volume":"30","author":"Sulter","year":"1999","journal-title":"Stroke"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/hjh.0000000000000972","article-title":"Effects of blood pressure lowering treatment in hypertension","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J. Hypertens."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1097\/hjh.0000000000001787","article-title":"Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality","volume":"36","author":"Thomopoulos","year":"2018","journal-title":"J. Hypertens."},{"key":"B35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamainternmed.2013.14764","article-title":"Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults","volume":"174","author":"Tinetti","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","article-title":"No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over","volume":"13","author":"Warwick","year":"2015","journal-title":"BMC Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy439","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J. Hum. Hypertens."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575\u00a0years","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"B40","volume-title":"The anatomical therapeutic chemical (ATC) classification system and defined daily dose (DDD) index","year":"2020"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.619088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T08:17:11Z","timestamp":1618906631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.619088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":40,"alternative-id":["10.3389\/fphar.2021.619088"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.619088","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"article-number":"619088"}}